Fulcrum Therapeutics, Inc. operates as a publicly traded corporation listed on the Nasdaq Global Market under the official ticker symbol FULC. As a public enterprise, it complies with comprehensive regulatory reporting standards, files regular quarterly and annual financial statements with the Securities and Exchange Commission, and holds public shareholder meetings, enabling institutional and retail investors to trade its shares openly based on clinical progress and corporate developments.